Day 3 with Cordyceps

We're on day 3 with the addition of Cordyceps as supplements for both my mom and me.

My blood pressure readings are wicked good these days. 98/67 is the average so far. Without the Cordyceps, my blood pressure averaged 117/80. It also stopped ALL MY HOT FLASHES AND NIGHT SWEATS!

My mom's blood sugar with the combination of Fenugreek Seed powder/extract and 2 Cordycep capsules with each meal is keeping her range between 86 and 127 (even after meals!)

Her memory is much better. She appears to be happier and smiling a lot more. She feels great. I can see that she has more energy. Yesterday she even vacuumed the carpeting in her room!

Next, I will teach my mom how to cook the new healthy way so that I can go out and get a job. Jo will take on the cooking tasks, something that I find myself doing all day long, cooking and cleaning up the kitchen. If my mom can do this, I'll be freed up to earn money so that we can do more additions and repairs around the house.

Here's more information about Cordyceps.

Dong Chong

Product Search

Cordyceps Sinensis

NIH Disease Links

CancerHepatitisDiabetesLeukemia

NIH Research Links

In VitroIn VivoClinical Trials

Cordyceps Sinensis

Cordyceps has a long history of therapeutic application and is well documented in western literature as immunologically modulating. The below compiled literature describes clinically significant benefits for a wide range of disease conditions related to immune competency.

Cordyceps Sinensis is a very cool mushroom; it eats insects and other fungi. This picture shows a cordyceps that has consumed a grub worm.

Cordyceps Sinensis contains a wide range of bio-theraputic agents, but the majority of benefits are associated with large molecule polysaccharides which exhibit clinically verified therapeutic actions. Myco-saccharides often have molecular weights exceeding 7000. Recent research correlates therapeutic benefit with size of the polysaccharide molecules.

See links below for research details. Here is a great pdf article on Cordyceps Sinensis. Did you know that 1 kilogram of wild-harvested Cordyceps costs about $250,000? Did you know that Cordyceps Sinensis harvest accounts for over half of Tibet's economy?

• Summary of Clinical/Scientific Data - Batch 2
• Summary of Clinical/Scientific Data - Batch 1
• Research Article Roundup for Cordyceps Sinensis
• John Holiday On the Trail of the Yak - The search for Cordyceps
• John Holiday - Hybridization of Cordyceps - What you need to know about quality
• Short Version -- Hybrid Cordyceps have 4-5x the potency of wild harvested ones.
• Here is a great article by Richard Miller on High Performance Cordyceps

Issued US Patents
Patent Link	Title	Research Indications
6,630,160	Process to modulate disease risk with doses of a nutraceutical	Cancer Risk
6,468,541	Natural, non-allergenic, immune system stimulant	Immune System Enhancement
6,007,813	Method and composition for treating ulcers and secretion of gastric acid	Performance Enhancement Ulcer Treatment
5,948,404	Healthful composition obtained from the hot water extract of Coryceps sinensis mycelia	Endurance, Heart Strength
5,939,072	Herbal composition and method of treating viral infection of the liver	Hepatitis
5,916,555	Pharmaceutical composition for treatment of diabetes	Diabetes
5,582,828	Active fractions of Cordyceps Sinensis and method of isolation thereof	Kidney Disease

Study Link	Clinical Study Conclusions
Pero 2005	Combining nutritional supplements to achieve synergistic benefit is a common practice in the nutraceutical industry. However, establishing added health benefit from a combination of natural ingredients is often assumed, untested and without regard to the principle of metabolic competition between the active components. Here, we report on the combination of a cat's claw water extract (C-Med-100, carboxy alkyl esters = active ingredients) + medicinal mushroom extracts (Cordyceps sinensis, Grifola blazei, Grifolafrondosa, Trametes versicolor and Ganoderma lucidum, polysaccharides = active ingredients) + nicotinamide + zinc into a formulation designed to optimize different modes of immunostimulatory action, and yet that would avoid metabolic antioxidant competition yielding less than expected efficacious effects. Isobole curve analyses of these two active classes of ingredients determined by growth inhibition of HL-60 human leukemic cells in vitro confirmed they were indeed synergistic when in combination, and not metabolically competitive. Furthermore, an in vivo study showed significant health benefit for 14 subjects treated for 4 weeks with the unique C-Med-100/mushroom extract formulation in that they had reduced pain, reduced fatigue, weight loss and a reduced presence of DNA damage in peripheral blood assessed by (8-OH) guanine DNA adducts and elevation in serum protein thiols. Because this broad-based panel of clinical parameters indicating clinical efficacy has never been demonstrated before for either of the active ingredients evaluated alone in humans, these data were taken as strong evidence that the combination of C-Med-100 + mushroom extracts + nicotinamide + zinc gave additive or synergistic effects to health benefit, and thus supported no efficacious limits from metabolic competition regarding this particular formulation.
Lu 2002	OBJECTIVE: To observe the effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis (LN). METHODS: Sixty-one LN patients, who had no activities by corticosterone and cyclophosphamide (CTX) impacting therapy were randomly divided into two groups. The 31 cases in the treated group were given Cordyceps powder 2-4 g/d before meal and artemisinin 0.6 g/d after meal in three portions orally taken for 3 years. The 30 patients in the control group were treated with tripterygiitotorum and/or Baoshenkang tablet. The consecutive observation lasted for 5 years to monitor the clinical manifestations of lupus and laboratory indexes including blood creatinine, creatinine clearance rate (CCr) and antinuclear antibodies (ANA). RESULTS: The therapeutic effect showed markedly effective in 26 cases (83.9%), effective in 4 (12.9%) and ineffective in 1 (3.2%) in the treated group, while in the control group, the corresponding numbers were 15 (50.0%), 8 (26.7%) and 7 (23.3%), the difference between the two groups in markedly effective rate was significant (P < class="style1" style="color: rgb(0, 0, 153); font-weight: bold; ">CONCLUSION: Cordyceps and artemisinin could prevent the recurrence of LN and protect kidney function.
Gao 2000	OBJECTIVE: To investigate the effect of cordyceps sinensis (CS) on the Th1/Th 2 cytokines and recurrence in patients with Condyloma Acuminatum (CA). METHOD: Double-antibody sandwich ELISA was used to study the serum level of IL-2 and IL-10 in 34 patients treated with CS(CS group) and 29 patients in control group. The recurrence rate of CA was observed. RESULT: After treated with CS, the serum levels of IL-2 and IL-10 significantly increased and decreased respectively (P < class="style2" style="color: rgb(0, 0, 255); font-weight: bold; "> The recurrence times of CA in patients of CS group after electrocauterization were significantly lower than control group (P <>
Gong 2000	In order to find an effective drug to cure patients with chronic hepatitis B, cordyceps sinensis had been used to treat 25 patients with chronic hepatitis B. The comprehensive index, including T lymphocyte subsets (CD4, CD8), hyaluronic acid(HC) and precollagen type III(PC III), were observed before and after treatment. After 3 months of treatment, CD4 and CD4/CD8 ratio increased significantly(P < class="style3" style="color: rgb(0, 0, 0); font-weight: bold; ">The results suggest that the beneficial effects might be obtained by using cordyceps sinensis to adjust the T lymphocyte subsets level and to treat hepatic fibrosis on patients with chronic hepatitis B.
Bao 1994	The protective effect on aminoglycoside nephrotoxicity by Cordyceps sinensis in the old patient was observed. 21 old patients were randomly divided into two groups. Each group received amikacin sulfate for 6 days. In addition, group A was administered Cordyceps sinensis for 7 days and group B was given placebo. The results revealed that group A developed less prominent nephrotoxicity compared with group B as evidenced by less urinary nephro-aminoglycosidase (NAGase) and beta-microglobulin in group A than those in Group B. These results suggested that Cordyceps sinensis exerted a protective effect on aminoglycoside nephrotoxicity in the old patients.
Zhou 1995	Jinshuibao Capsule (JSBC), produced by Jiangxi Jinshuibao pharmaceutical Company Limited, possesses the similar active principles and pharmacological activity with those of Cordyceps sinensis. The effect of JSBC on the immunological function of 36 patients with advanced cancer showed that it could restore cellular immunological function, improve quality of life, but had no significant effect on humoral immunological function. The results suggested that JSBC could be used as adjuvant drug in advanced cancer.